VivoSeq
Other

Carvedilol

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Carvedilol is an early-stage landscape with 0 programs across 2 companies. The most active players are Mylan Pharmaceuticals Inc, Elpen Pharmaceutical Co. Inc..

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

94/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc

0 programs

PreclinicalE

Elpen Pharmaceutical Co. Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

19

clinical trials

Completed15 · 79%
Unknown status3 · 16%
Terminated1 · 5%

Clinical Trials

Trial Activity

19 trials

Effects of Carvedilol on Cocaine Use in Humans - 11
Completed·National Institute on Drug Abuse (NIDA)·Phase 2·NCT00000294
Fed Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg
Completed·Mylan Pharmaceuticals Inc logoMylan Pharmaceuticals Inc·Phase 1·NCT00648622·50 enrolled
Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril
Completed·SState University of New York at Buffalo·Phase 3·NCT00657241·30 enrolled
Carvedilol Post-intervention Long-term Administration in Large-scale Trial
Completed·—·Phase 4·NCT01155635·801 enrolled
Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fed Conditions
Completed·—·Phase 1·NCT01064180·24 enrolled
Cytochrome P450 2D6 Genotype on the Clinical Effect of Carvedilol
Completed·SSeoul National University Hospital·Phase 1·NCT02286934·24 enrolled
The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment
Completed·UUniversity of Utah·N/A·NCT00585091·15 enrolled
Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fed Conditions
Completed·RRanbaxy Laboratories Limited·N/A·NCT00775619·40 enrolled
Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg
Completed·Mylan Pharmaceuticals Inc logoMylan Pharmaceuticals Inc·Phase 1·NCT00650416·50 enrolled
Effect of Carvedilol on Exercise Performance in Fontan Patients
Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT02946892·26 enrolled
Carvedilol for Psychostimulant Dependence
Completed·UUniversity of Arkansas·Phase 2·NCT01171183·32 enrolled
Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD
Completed·VVA Greater Los Angeles Healthcare System·Phase 4·NCT03370835·21 enrolled
Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting Condition
Completed·IIPCA Laboratories Ltd.·Phase 1·NCT01577914·42 enrolled
Study to Evaluate the Safety of Twice Daily Oral Carvedilol
Completed·—·Phase 3·NCT00129363·75 enrolled
Carvedilol Vascular Efficacy Trial
Completed·EElpen Pharmaceutical Co. Inc.·N/A·NCT01484327·415 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)